Cystatins in non-small cell lung cancer: Tissue levels, localization and relation to prognosis

Oncology Reports

Volumn 16, Issue 4, 2006, Pages 647-655

  Werle, Bernd ^a,b   Schanzenbächer, Ulrike ^a   Lah, Tamara Turensek ^e   Ebert, Eileen ^a   Jülke, Britta ^a   Ebert, Werner ^a   Fiehn, Werner ^b   Kayser, Klaus ^d   Spiess, Eberhard ^c   Abrahamson, Magnus ^g   Kos, Janko ^f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^f UNIVERSITY OF LJUBLJANA   (Slovenia)

^g LUND UNIVERSITY   (Sweden)

Author keywords

Cathepsin; Cystatin; Cysteine protease; Non small cell lung cancer; Prognosis; Stefin

Indexed keywords

CST7 PROTEIN, HUMAN; CYSTATIN; CYSTATIN C; CYSTATIN E; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYSTATINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845286615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.4.647     Document Type: Article

References (50)

1. Rawlings ND and Barrett AJ: Evolution of proteins of the cystatin superfamily. J Mol Evol 30: 60-71, 1999.
2. Henskens YMC, Veerman ECI and Amerongen AVN: Cystatins in health and diseases. Biol Chem Hoppe-Seyler 377: 71-86, 1996.
3. Pierre P and Mellman I: Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 93: 1135-1145, 1998. (Pubitemid 28307419)
4. Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F and Vray B: Chicken cystatin stimulates nitric oxide release from interferon-g-activated mouse peritoneal macrophages via cytokine synthesis. Eur J Biochem 266: 1111-1117, 1999. (Pubitemid 30010130)
5. Giaimo R, Riccio M, Santi S, Galeotti C, Ambrosetti DC and Melli M: New insights into the molecular basis of progressive myoclonus epilepsy. A multiprotein complex with cystatin B. Hum Mol Genet 23: 2941-2950, 2002.
6. Taupin P, Ray J, Fischer WH, et al: FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron 28: 385-390, 2000.
7. Sokol JP and Schiemann WP: Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res 2: 183-189, 2004.
8. Kos J and Lah TT: Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncol Rep 5: 1349-1361, 1998. (Pubitemid 28474074)
9. Pennacchio LA, Lehejoski AE, Stone NE, et al: Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271: 1731-1734, 1996. (Pubitemid 26102822)
10. Palsdottir M, Abrahamson M, Thorsteinsson L, Arnason A, Olafsson I, Grubb A and Jensson O: Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 8611: 603-604, 1998.
11. Trefz G, Lüthgens K, Erdel M, Spiess E and Ebert W: Plasminogen activator and cathepsin B in normal and malignant human lung tissue. J Cancer Res Clin Oncol 115: 50-58, 1998.
12. Sedo A, Krepela E and Kasafirek E: Dipeptidylpeptidase IV, prolylendopeptidase and cathepsin B activities in primary human lung tumors and lung parenchyma. J Cancer Res Clin Oncol 117: 249-253, 1991.
13. Ebert W, Knoch H, Werle B, Trefz G, Muley T and Spiess E: Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res 14: 895-900, 1994. (Pubitemid 2123973)
14. Werle B, Jülke B, Lah T, Spiess E and Ebert W: Cathepsin B fraction active physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. Br J Cancer 75: 1137-1143, 1997. (Pubitemid 27140024)
15. Werle B, Kraft C, Lah TT, Kos J, Schanzenbächer U, Kayser K, Ebert W and Spiess E: Cathepsin B in infiltrated lymph nodes is of prognostic significance for non-small cell lung cancer patients. Cancer 89: 2282-2291, 2000.
16. Krepela E, Kasafirek E, Novak K and Vyklicky J: Increased cathepsin B activity in human lung tumors. Neoplasma 37: 61-70, 1990. (Pubitemid 20146699)
17. Krepela E, Prochazka J, Karova B, Cermak J and Roubkova H: Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer. Neoplasma 45: 318-331, 1998. (Pubitemid 29010682)
18. Tsushima H, Sumi H, Mihara H, Joronen J and Hopsu-Havu VK: Cysteine proteinase inhibitors in human melanoma transplanted into nude mice. Biol Chem Hoppe-Seyler 369: 243-250, 1988.
19. Sheahan K, Shuja S and Murnane MJ: Cysteine protease activities and tumour development in human colorectal carcinoma. Cancer Res 49: 3809-3814, 1989. (Pubitemid 19197402)
20. Sloane BF, Rozhin J, Robinson D and Honn KV: Role for cathepsin B and cystatins in tumour growth and progression. Biol Chem Hoppe-Seyler 371: 193-198, 1990. (Pubitemid 20331102)
21. Lah TT, Kokalj-Kunovar M, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, Kastelic L, Babnik J, Golouh R and Turk V: Stefins and lysosomal cathepsin B, L and D in human breast carcinoma. Int J Cancer 50: 36-44, 1992.
22. Ebert E, Werle B, Jülke B, et al: Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 421: 259-265, 1997. (Pubitemid 27432679)
23. Zore I, Krasovec M, Cimerman N, et al: Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol Chem 382: 805-810, 2001. (Pubitemid 32631718)
24. Manegold C and Drings P: Chemotherapie des nichtkleinzelligen Lungenkarzinoms. In: Thoraxtumoren: Diagnostik - Staging - gegenwärtiges Therapiekonzept. Drings P and Vogt-Moykopf I (eds). Springer Verlag, Heidelberg, pp310-327, 1998.
25. Schraube P, Kimming B, Latz D, Flentje M and Wannenmacher M: Radiotherapie des Bronchialkarzionms. In: Thoraxtumoren: Diagnostik - Staging - gegenwärtiges Therapiekonzept. Drings P and Vogt-Moykopf I (eds). Springer Verlag, Heidelberg, pp277-295, 1998.
26. Kayser K and Gabius HJ: Graph theory and the entropy concept in histochemistry. Theoretical consideration, application in histopathology and the combination with receptor-specific approaches. In: Progress in Histochemistry and cytochemistry. Graumann W, Bendayan M, Bosman FT, Heitz PU, Larsson LI and Wolfe HJ (eds). Gustav Fisher, Stuttgart, Jena, Lübeck, Ulm, pp32-39, 1997.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgramm quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
28. Ebert W, Knoch H, Werle B, Treftz G, Muley T and Spiess E: Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res 14: 895-899, 1994. (Pubitemid 24272541)
29. Kos J, Smid A, Krasevec M, et al: Lysosomal proteases Cathepsins D, B, H, L and their inhibitors stefins A and B in Head and neck cancer. Biol Chem Hoppe-Seyler 376: 401-405, 1995.
30. Olafsson I, Löfberg M, Abrahamson M and Grubb A: Production, characterization and use of monoclonal antibodies against the major extracellular human cysteine proteinase inhibitors cystatin C and kininogen. Scand J Clin Lab Invest 48: 573-582, 1988.
31. Ni J, Abrahamson M, Zhang M, et al: Cystatin E/M, a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J Biol Chem 272: 10853-10858, 1997. (Pubitemid 27181102)
32. Ni J, Alvarez-Fernandez M, Danielsson L, et al: Cystatin F is a glycosylated human low-Mr cysteine proteinase inhibitor. J Biol Chem 273: 24797-24804, 1998. (Pubitemid 28454984)
33. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
34. Cox DR: Regression models and life tables (with discussion): J R Stat Soc 187: 187-220, 1972.
35. Abel U, Berger J and Wiebelt H: Critlevel. An exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med 23: 154-156, 1984. (Pubitemid 14002516)
36. Sameni M, Dosescu J, Moin K and Sloane BF: Functional imaging of proteolysis: Stromal and inflammatory cells increase tumor proteolysis. Mol Imaging 2: 159-175, 2003.
37. Cox JL, Sexton PS, Green TJ and Darmani NA: Inhibition of B16 melanoma metastasis by overexpression of the cysteine protease inhibitor cystatin C. Melanoma Res 9: 369-374, 1999. (Pubitemid 29407069)
38. Strojan P, Budihna M, Smid L, et al: Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 6: 1052-1062, 2000. (Pubitemid 30159367)
39. Strojan P, Oblak I, Svetic B, Smid L and Kos J: Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer 90: 1961-1968, 2004. (Pubitemid 38746337)
40. Huh CG, Häkansson K, Nathanson CM, et al: Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. J Clin Pathol Mol Pathol 52: 332-340, 1999. (Pubitemid 30002765)
41. Kos J, Werle B, Lah T and Brunner N: Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer. Int J Biol Markers 15: 84-89, 2000. (Pubitemid 30195490)
42. Foghsgaard L, Wissing D, Mauch D, et al: Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biology 153: 999-1009, 2001. (Pubitemid 34289239)
43. Chapman HA, Riese JR and Shi GP: Emerging roles for cysteine proteinases in human biology. Annu Rev Physiol 59: 63-88, 1997. (Pubitemid 27142435)
44. Kos J, Sekirnik A, Kopitar G, et al: Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer 85: 1193-1200, 2001. (Pubitemid 33052320)
45. Tate S, Ushioda T, Utsonomiya-Tate N, et al: Solution structure of human cystatin A variant, cystatin A2-98 M65L, by NMR spectroscopy. A possible role of the interaczions between the Nand C-termini to maintain the inhibitory active form of cystatin A. Biochemistry 34: 14637-14648, 1995.
46. Langerholc T, Zavasnik-Bergant V, Turk B, Turk V, Abrahamson M and Kos J: Inhibitory properties of cystatin F and its localisation in U937 promonocyte cells. FEBS J 272: 1535-1545, 2005. (Pubitemid 40444941)
47. Alvarez-Fernandez M, Barrett AJ, Gerhartz B, Dandi PM, Ni J and Abrahamson M: Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem 274: 19195-19203, 1999.
48. Morita M, Hara Y, Tamai Y, Arakawa H and Nishimura S: Genomic construct and mapping of the gene for CMAP (leukocystatin/cystatin F, CST7) and identification of a proximal novel gene BSCv (C20orf3). Genomics 67: 87-91, 2000. (Pubitemid 30471125)
49. Vigneswaran N, Wu J and Zacharias W: Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumour to metastasis. Eur J Cancer B Oral Oncol 39: 559-568, 2003. (Pubitemid 36694479)
50. Sotiropoulu G, Anisowicz A and Sager R: Identification, cloning, and characterisation of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem 272: 903-910, 1997. (Pubitemid 27034580)